Capital Fund Management S.A. Increases Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Capital Fund Management S.A. boosted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 116.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,277 shares of the medical device company's stock after purchasing an additional 107,587 shares during the period. Capital Fund Management S.A. owned approximately 0.30% of Tandem Diabetes Care worth $7,214,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TNDM. Raymond James Financial Inc. purchased a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $5,893,000. Renaissance Technologies LLC increased its holdings in Tandem Diabetes Care by 50.0% during the 4th quarter. Renaissance Technologies LLC now owns 315,727 shares of the medical device company's stock worth $11,372,000 after purchasing an additional 105,300 shares during the last quarter. FIL Ltd raised its position in shares of Tandem Diabetes Care by 48.7% in the 4th quarter. FIL Ltd now owns 201,376 shares of the medical device company's stock valued at $7,254,000 after purchasing an additional 65,984 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Tandem Diabetes Care by 4.3% during the 4th quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock valued at $360,000 after buying an additional 409 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of Tandem Diabetes Care by 36.5% during the fourth quarter. Russell Investments Group Ltd. now owns 290,228 shares of the medical device company's stock worth $10,454,000 after buying an additional 77,594 shares in the last quarter.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 2.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on TNDM shares. Robert W. Baird cut their price target on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Wells Fargo & Company reissued an "equal weight" rating and issued a $22.00 price objective (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Royal Bank of Canada cut their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Mizuho assumed coverage on Tandem Diabetes Care in a research report on Thursday. They issued a "neutral" rating and a $20.00 target price for the company. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.88.

Remove Ads

Tandem Diabetes Care Stock Performance

TNDM opened at $17.06 on Friday. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The stock has a market cap of $1.13 billion, a PE ratio of -8.84 and a beta of 1.52. The business's 50 day moving average is $23.62 and its 200-day moving average is $30.91. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.